AB Science S.A.

Paris Stock Exchange AB.PA

AB Science S.A. Return on Assets (ROA) for the year ending December 31, 2023: -39.41%

AB Science S.A. Return on Assets (ROA) is -39.41% for the year ending December 31, 2023, a 31.00% change year over year. Return on assets measures profitability against assets; higher ROA indicates efficient asset use and profitability.
  • AB Science S.A. Return on Assets (ROA) for the year ending December 31, 2022 was -57.11%, a 16.01% change year over year.
  • AB Science S.A. Return on Assets (ROA) for the year ending December 31, 2021 was -67.99%, a -34.17% change year over year.
  • AB Science S.A. Return on Assets (ROA) for the year ending December 31, 2020 was -50.68%, a 58.66% change year over year.
  • AB Science S.A. Return on Assets (ROA) for the year ending December 31, 2019 was -122.59%, a -5.80% change year over year.
Key data
Date Return on Assets (ROA) Return on Equity (ROE) Return on Capital Employed (ROCE) Interest Coverage Ratio
Market news
Loading...
SV Wall Street
Paris Stock Exchange: AB.PA

AB Science S.A.

CEO Mr. Alain Moussy MBA
IPO Date April 26, 2010
Location France
Headquarters 3, Avenue George V
Employees 40
Sector Health Care
Industries
Description

AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company also develops AB8939, synthetic microtubule destabilizer for the treatment of acute myeloid leukemia; and AB20001, which is in Phase 2 clinical trial to evaluate the safety and efficacy of masitinib combined with isoquercetin in hospitalized patients with moderate and severe COVID-19. It markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.

Similar companies

ADOC.PA

Adocia SA

USD 6.11

-1.79%

NANO.PA

Nanobiotix S.A.

USD 3.56

1.19%

GNFT.PA

Genfit S.A.

USD 3.82

3.95%

IPH.PA

Innate Pharma S.A.

USD 1.82

1.45%

StockViz Staff

January 31, 2025

Any question? Send us an email